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Abstract
Purpose Neuroendocrine tumours (NET) are a heteroge-
neous group of neoplasms of diffuse neuroendocrine cells.
Surgery is the main aim in the treatment of NETs, which
becomes impossible in the case of large tumours or
infiltration into other tissues and/or important blood
vessels. Neoadjuvant therapy might be helpful in decreas-
ing NET size also, leading us to the point where a tumour,
previously considered inoperable, becomes operable. The
aim of the study was to assess the usage of peptide receptor
radionuclide therapy (PRRT) as a neoadjuvant treatment,
enabling surgical intervention in primary inoperable NET.
Methods Among 47 patients treated with PRRT, 6 patients
were chosen with large, inoperable tumours, for whom
enabling of complete surgical excision of the lesions might
offer the prospect for a cure. Response to the therapy was
assessed according to Response Evaluation Criteria In Solid
Tumors (RECIST).
Results The mean tumour size decreased from 6.9 (min.
3.1 cm, max. 9.6 cm) before therapy to 5.4 cm
(min. 3.1 cm, max. 9.5 cm) after the treatment. According
to RECIST, stabilization of the disease was observed in
four and partial responses in two patients. In two patients,
reduction of the tumour size enabled surgical intervention.
Conclusion (1) PRRT might be considered a neoadjuvant
therapy in primary inoperable NETs. (2) According to
RECIST, stabilization of the disease was observed in the
majority of patients. (3) We suggest that not only tumour
diameter changes, but also tumour volume and contrast
enhancement changes in computed tomography should be
taken into consideration in assessment of the response to
the therapy. (4) Somatostatin receptor scintigraphy is an
important tool for qualification of the radioisotope therapy
and also for the assessment of the response to PRRT.
Keywords Neuroendocrine tumours.Peptide receptor
radionuclide therapy.Neoadjuvant therapy
Introduction
Neuroendocrine tumours (NET) are a rare, potentially
malignant, usually slow-growing, mostly well-
differentiated, heterogeneous group of neoplasms of neuro-
endocrine cells, characterized by their ability to secrete
hormones [1]. Surgical eradication is the main aim in the
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largetumoursorinfiltrationintoothertissuesand/orimportant
blood vessels. Palliative surgical intervention is performed to
diminish clinical symptoms and improve the patient’sq u a l i t y
oflife[2, 3]. Another method of therapy used in patients with
NETs is chemotherapy. Combined chemotherapy (e.g.
cisplatin with etoposide) following incomplete surgical
eradication might be considered also in patients with
disseminated disease. But this kind of treatment has rather
a low efficacy. To decrease tumour size, change it from
untreatable to removable and make the surgical intervention
possible and more effective, neoadjuvant therapy is per-
formed on oncological illnesses (e.g. breast cancer) [4].
Neoadjuvant therapy might be helpful in decreasing NET
size also, leading us to the point where a tumour, previously
considered inoperable, becomes operable. There are few data
on substances such as somatostatin analogues and interferon
or on chemotherapy with cisplatin and etoposide used as
neoadjuvant therapy. There are ongoing clinical trials of
some novel targeted therapies [5]. Based on the fact that
neuroendocrine neoplasms usually express somatostatin
receptors, peptide receptor radionuclide therapy (PRRT) can
also be used to decrease the size of the tumour and make
surgical intervention possible [3]. The aim of the study was
to assess the usage of PRRT as a neoadjuvant treatment
leading to a decrease in the size of the tumour and enabling
surgical intervention in primary inoperable NETs.
Materials and methods
Among the group of 47 patients treated with PRRT, 6
patients were chosen with large, inoperable tumours, for
whom enabling of complete surgical excision of the lesions
might offer the prospect for a cure. Only one of those
patients had potentially removable liver metastases. All of
the patients included in the therapy had positive somato-
statin receptor scintigraphy (SRS) scans obtained with the
use of
99mTc-EDDA/HYNIC-TOC, and every patient was
in good general condition (Karnofsky index > 70–100%).
There were three men and three women. The mean age was
58.6 years (± 12.0 years, min. 46.0 years, max. 78.0 years).
Among the patients included in the therapy with
90Y-
DOTA-TATE due to inoperable NET, there were five
patients with foregut tumours, among them three with
pancreatic NETs and one with midgut tumour. The patient
with midgut tumour presented at the time of diagnosis with
diarrhoea and weight loss. The mean tumour size before
t h e r a p yw a s6 . 9c m( m i n .3 . 1c m ,m a x .9 . 6c m ) .
Cytoreduction chemotherapy or long-acting somatostatin
analogue were not used before PRRT. Only one patient
received chemotherapy prior to PRRT, but there was no
response observed in tumour size after that treatment.
Methods
Every patient received a dose of 7.4 GBq/m
29 0 Y-DOTA-
TATE in 4–5 cycles every 6–9 weeks. The mean dose was
13.6 GBq (min. 11.1 GBq, max. 14.8 GBq). Response to
the therapy was assessed according to Response Evaluation
Criteria In Solid Tumors (RECIST).
SRS with
99mTc-EDDA/HYNIC-TOC was performed
before and 1, 6 and 12 months after PRRT. The tracer used
was produced fulfilling GMP criteria (POLATOM, Świerk,
Poland). The diagnostic procedure was carried out in the
Nuclear Medicine Unit of the Endocrinology Department,
Cracow University Hospital. The first vial (containing
stannous chloride, mannitol, tricine and EDDA) were
completed with 1 ml of water for injection. Then 0.5 ml
from the first vial was added to the second vial containing
HYNIC-TOC. Next the tracer was labelled with 1–2m lo f
99Mo/
99mTc generator eluate (1–1.5 GBq) followed by
20 min incubation at 80°C. The detailed method of kit
labelling with
99mTc has been presented earlier [6].
A dual-head, large field of view Proven Excellence e.
cam variable angle gamma camera (Siemens) with parallel,
low-energy, high-resolution (LEHR) collimators was used.
After injection of the tracer (740 MBq), all patients
underwent whole-body scans after 1, 4 and 24
h (256×1,024 matrix, 12 cm/min, 8 cm/min, 6 cm/min,
respectively) and single photon emission computed tomog-
raphy (SPECT) of the abdomen and/or thorax (180° orbit
for each head, step-and-shoot mode, 64 images, at 30 s per
view, 128 × 128 matrix). The acquired data were
reconstructed using iterative reconstruction ordered subset
expectation maximization (OSEM) 3-D FLASH (8 subsets
and 10 iterations).
Before and 1–3, 6 and 12 months after the treatment, CT
examinations were performed in the First CT Unit of the
Radiology Department using a spiral multirow Siemens
Somatom Sensation 16 CT scanner and standard protocols:
(1) for abdomen and pelvis (detector configuration 16 ×
0.75 mm, slice thickness and reconstruction increment 0.2
cm, reconstruction kernel B31f, before and multiphase after
i.v. nonionic contrast media administration in a dose of 1
ml/kg, flow 2.5 ml/s, delay of arterial phase 30 s and
venous phase 60 s after the start of contrast administration);
(2) for chest (detector configuration 16 × 0.75 mm, slice
thickness and reconstruction increment 2 mm, reconstruc-
tion kernel B41f, before and after i.v. nonionic contrast
media administration in a dose of 1 ml/kg, flow 2.5 ml/s,
delay 30 s after the start of contrast administration).
Additional linear measurements of focal lesions were
performed on a Siemens Wizard workstation using the tools
of CT images’ browser. Volume measurements of focal
lesions were performed on the Siemens Wizard workstation
using the dedicated volume application. For every lesion,
1670 Eur J Nucl Med Mol Imaging (2011) 38:1669–1674its borders were manually marked on consecutive slices of
the CT examination. The measurement included pixels with
CT attenuation values from −30 to 200 HU to eliminate
lesions such as calcifications which influence the attenua-
tion. Then, the program automatically calculated the
volume and average attenuation of the lesion.
Chromogranin A (CGA) level, a nonspecific marker of
NETs, was measured prior to and 6 months after PRRT in
all patients [7].
Results
The mean tumour size decreased from 6.9 (min. 3.1 cm,
max. 9.6 cm) before therapy to 5.4 cm (min. 3.1 cm, max.
9.5 cm) after the treatment. According to RECIST,
stabilization of the disease was observed in four and partial
responses in two patients. In the case of patient 6 (Table 1,
Fig. 1), the tumour size 1 month after PRRT decreased from
11.0 (before the treatment assessed on X-ray photos) to 7.2
cm (the longest diameter of lesions on axial CT slices). Five
months later, a further decline in the tumour size to 5.7 cm
was observed. Reduction of the tumour size after neo-
adjuvant PRRT enabled qualification for a laparotomy,
which was performed 11 months after PRRT. Due to
infiltration of the large vessels, which was visible on CT
scans, only partial removal of the tumour was possible. The
patient qualified for additional PRRTcourses. An additional
three PRRT courses were given and further resection of the
t u m o u rs i z e( f r o m5 . 7a f t e rs u r g e r yt o3 . 6c m )w a s
considered, but the tumour remains still inoperable.
The second patient (patient 2 in Table 1, Fig. 2) with
partial response qualified for surgery. After the PRRT, the
tumour size decreased from 7.9 to 4.2 cm and there was no
evidence of the liver metastases observed prior to PRRT.
Whether complete tumour removal can be achieved is an
open question.
The mean time of observation was 21.5 months (± 15.3,
min. 6.0 months, max. 46.0 months). The median CGA
decreased from 33.4 (min. 12.8 U/l, max. 268.7 U/l) to
27.15 U/l (min. 21.8 U/l, max. 36.3 U/l). No correlation
between tumour size and uptake intensity and CGA was
observed. PRRT did not cause myelotoxicity or nephrotox-
icity.
Discussion
Neoadjuvant therapy is a kind of induction therapy leading
to shrinkage of the tumour, which enables surgical
intervention. It is widely used in different types of cancers
(e.g. breast cancer) and may include chemotherapy,
radiotherapy and/or hormone therapy [4]. There are also
possibilities for neoadjuvant therapy in the case of NETs, as
mentioned above. PRRT might be also considered as a
neoadjuvant therapy in the case of NETs [3, 8].
Expression of somatostatin receptors on the surface of
NETs became the molecular basis for the use of somato-
statin analogues in the diagnosis and therapy of these
neoplasms. PRRT with the use of labelled somatostatin
analogues has been applied in disseminated and inoperable
NETs with positive somatostatin receptor expression con-
firmed by SRS.
The results of our study indicate, as also presented by
Kaemmerer et al., that PRRT might be considered not only
as a palliative but also as a neoadjuvant therapy in primary
inoperable NETs [3]. In the case presented by Kaemmerer
et al., PRRT and the following surgical intervention led to
complete remission of the disease. In another case
described recently by Stoeltzing et al. after surgical removal
of the large primary tumour of the pancreatic tail
90Y-
DOTATOC was used with neoadjuvant intention resulting
in a regression of hepatic lesions and facilitating surgical
removal of all remaining liver metastases in a second
operation [8]. In our study we observed reduction in the
tumour size/volume in two of the patients with primary
inoperable tumours. In one case (patient 6 in Table 1),
PRRT enabled surgical intervention, but complete resection
of the tumour was not possible due to infiltration of the
Table 1 Quantitative evaluation in CT of diameter, volume and
attenuation of tumour before and 6 months after PRRT
Patient 1 2 3 4 5 6
Sex F M M M F M
Age 78 56 61 70 59 48
D prior to PRRT
(cm)
3.4 7.9 3.1 9.6 5.8 7.2
V prior to PRRT
(cm
3)
19.9 230.9 3.8 301.5 75.8 208.3
A prior to PRRT
(HU)
56.8 28.5 46.7 70.8 68 44.9
D after PRRT
(cm)
3.4 4.2 3.1 9.5 6.5 5.7
V after PRRT
(cm
3)
19.8 44.7 3.7 336.2 84.0 82.4
A after PRRT
(HU)
62.9 29.5 42.5 53.2 59.8 40.5
Response to the
therapy
a
SD PR SD SD SD PR
D change (%) 0 −47.8 0 −1.0 12.1 −20.7
V change (%) −0.6 −80.7 −1.1 11.5 10.9 −60.7
A change (%) 10.7 3.5 9.0 −24.9 −12.1 −9.8
D diameter, V volume, A attenuation, SD stabilization of the disease,
PR partial response
aResponse to the therapy according to RECIST, which includes
measurement of the longest diameter of every measurable lesion on
axial CT slices and calculation of the sum of the longest diameters for
all selected target lesions
Eur J Nucl Med Mol Imaging (2011) 38:1669–1674 1671Fig. 1 A 48-year-old man with inoperable midgut tumour (patent 6). The results of
99mTc-EDDA/HYNIC-TOC SRS, CT and SRS/CT fusion
image before (a) and after (b) the neoadjuvant therapy with PRRT are presented
Fig. 2 A 56-year-old man with inoperable pancreatic NET (patient 2). The results of
99mTc-EDDA/HYNIC-TOC SRS, CT and SRS/CT fusion
image before (a) and after (b) the neoadjuvant therapy with PRRT are presented
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which led to further reduction in the tumour size. The
second patient (patient 2 in Table 1) with partial response
has qualified for surgery. This patient presented with liver
metastases prior to PRRT, and there was no evidence of
hepatic lesions after radioisotope therapy. These results
show the potential role of PRRTas a neoadjuvant treatment.
Moreover, the use of PRRTas neoadjuvant therapy does not
have to be limited to patients with NETs with inoperable
primary tumour without dissemination, but as suggested by
Stoeltzing et al. and what was also seen in the case of one
of the patients treated in our centre, might be considered
also in patients with liver metastases [8].
We also analysed the results of the CT scans performed
prior to and after the treatment. The assessment according
to RECIST [9, 10] includes measurement of the longest
diameter of every measurable lesion on axial CT slices and
calculation of the sum of the longest diameters (SLD) for
all selected target lesions.
For partial response (PR), at least a 30% decrease in the
SLD of target lesions should be found, taking the baseline
SLD as reference. However, it should be remembered that
the volume changes proportionally to the cube of the linear
measurement, so assessment of the linear diameter change
may only insufficiently estimate the volume difference in
the course of treatment. Another inconvenience of the
RECIST standard is that it takes into consideration only the
size of lesions, with no assessment of structural changes in
the course of treatment, manifesting on CT as changes of
X-ray attenuation values (reduction of attenuation, weaker
contrast enhancement as the effect of neoplastic tissue
necrosis). In one of the cases analysed in this paper (patient
4 in Table 1), in spite of no significant tumour diameter
reduction (decrease of linear diameter by about 1%), an
average lesion attenuation decreased by about 24.9%,
probably as the effect of therapy. In another case (patient
6 in Table 1), there was no possibility to assess a CT scan
performed prior to the PRRT (only an X-ray photo version
from 2005 was available). Therefore, the CT scan 1 month
after PRRT was compared with a scan performed 6 months
after radioisotope therapy. In the CT scan before the
treatment, the size of the tumour was 11.0 cm. In our
analysis 1 and 6 months after the treatment, we observed a
significant decrease in neoplastic tissue volume of about
60.7%, but the SLD decrease was only 20.7%. In another
group of patients with NETs, treated in our department with
90Y-DOTA-TATE and/or
177Lu-DOTA-TATE, we also
observed a similar discrepancy with significant decrease
in lesion volume and only slight SLD decrease, assessed as
stabilization of the disease according to RECIST. In some
neoplasms characterized by good vascularization, modified
standards of therapy response are used more and more
commonly in CT, taking into consideration attenuation
changes, for example the Choi criteria for gastrointestinal
stromal tumour (GIST) and modified RECIST for hepato-
cellular cancer [11, 12]. Because NET lesions are mostly
well-vascularized neoplasms, a rational solution would be
the drawing up of CT assessment criteria for such lesions,
taking into consideration attenuation and contrast enhance-
ment changes in the course of treatment.
We would like to emphasize also a role of scintigraphy
in evaluating disease and in assessment of the response to
the therapy. Scintigraphy is an important tool for qualifica-
tion of the radioisotope therapy and also for the assessment
of the response to PRRT. The best option is to assess both
scintigraphy and CT together, which may give more
information about staging of the disease.
Conclusion
1. PRRT might be considered a neoadjuvant therapy in
primary inoperable NETs.
2. According to RECIST stabilization of the disease
was observed in the majority of patients. In two
patients, reduction of the tumour size enabled
surgical intervention.
3. We suggest that not only tumour diameter changes, but
also tumour volume and contrast enhancement changes
on CT should be taken into consideration in assessment
of the response to the therapy.
4. SRS is an important tool for qualification of the
radioisotope therapy and also for the assessment of
the response to PRRT.
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